Earnings summaries and quarterly performance for PharmaCyte Biotech.
Executive leadership at PharmaCyte Biotech.
Board of directors at PharmaCyte Biotech.
Research analysts covering PharmaCyte Biotech.
Recent press releases and 8-K filings for PMCB.
PharmaCyte Biotech Monetizes Femasys Stake, Boosts Cash
PMCB
New Projects/Investments
M&A
- PharmaCyte Biotech has strengthened its financial position by monetizing its stake in Femasys Inc., increasing its cash and marketable securities from $13.3 million to approximately $20 million.
- This decision reflects PharmaCyte's strategic capital allocation approach and was influenced by Femasys's financial challenges, which include negative margins and a high debt-to-equity ratio of 1.85.
- Following the announcement, PharmaCyte's stock price surged by 27.51% to $0.83.
Nov 25, 2025, 2:35 PM
PharmAla Launches NEXUS Portal and Announces Management Changes
PMCB
Product Launch
Management Change
Board Change
- PharmAla Biotech Holdings Inc. launched NEXUS, a new tool to connect prescribers, therapists, and clinic managers for MDMA practitioners, aiming to improve care delivery and knowledge sharing.
- The company announced the appointment of Farnoud Kazemzadeh as its new Chief Operating Officer.
- Dr. Harriet De Wit resigned from PharmAla's board of directors.
Oct 8, 2025, 12:55 PM
PharmaCyte Biotech Increases Stake in TNF Pharmaceuticals
PMCB
New Projects/Investments
M&A
- PharmaCyte Biotech, Inc. (PMCB) has increased its stake in TNF Pharmaceuticals (TNFA) by an additional $3 million.
- This investment supports TNF's recent license acquisition from LightSolver, Ltd., for a revolutionary processing accelerator that uses light for computation.
- The LightSolver technology is designed to reduce energy output by 90% and offers greater speed and efficiency than conventional computing methods, with applications in cryptocurrency mining and blockchain.
- TNF Pharmaceuticals is expected to change its name and ticker symbol to align with its new strategic focus.
- As of April 30, 2025, PharmaCyte Biotech remains well-capitalized with over $55 million in total assets.
Sep 2, 2025, 1:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more